Cryo Cell International (CCEL) Net Income towards Common Stockholders (2010 - 2026)
Cryo Cell International (CCEL) posted quarterly Net Income towards Common Stockholders of $554586.0 for Q2 2026, up 55.88% year-over-year from $355785.0 in Q2 2025, and up 1077.27% quarter-over-quarter from $47108.0 in Q1 2026.
Cryo Cell International (CCEL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Cryo Cell International (CCEL) has reported Net Income towards Common Stockholders for 17 consecutive years, with $554586.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 55.88% year-over-year to $554586.0; the TTM figure through May 2026 stood at -$2.3 million (down 214.61% YoY), while the FY2025 annual figure was -$2.2 million, down 187.54% from the prior year.
- Net Income towards Common Stockholders advanced to $554586.0 in Q2 2026 per CCEL's latest filing, from $47108.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.5 million in Q4 2022 and bottomed at -$16.9 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$603632.2 across 5 years, with a median of $555413.5 in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 613.93% — and 2025, when it plunged 1307.08%.
- Cryo Cell International's Net Income towards Common Stockholders stood at $1.5 million in 2022, then slumped by 1250.13% to -$16.9 million in 2023, then soared by 101.79% to $301001.0 in 2024, then slumped by 1307.08% to -$3.6 million in 2025, then jumped by 115.26% to $554586.0 in 2026.
- Business Quant data shows CCEL's Net Income towards Common Stockholders at $554586.0 in Q2 2026, $47108.0 in Q1 2026, and -$3.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 88.19 Bn | 90.61 Bn | 15.19 Bn | 1.93 Bn |
| 2 | Tenet Healthcare | 21.59 Bn | 21.56 Bn | 4.45 Bn | 826.00 Mn |
| 3 | Encompass Health | 12.19 Bn | 12.86 Bn | 1.34 Bn | -600,000.00 |
| 4 | Davita | 11.52 Bn | 12.39 Bn | 1.16 Bn | 343.22 Mn |
| 5 | Ensign | 10.59 Bn | 10.27 Bn | 306.24 Mn | 99.83 Mn |
| 6 | Universal Health Services | 8.79 Bn | 8.72 Bn | 3.29 Bn | 358.45 Mn |
| 7 | Pacs | 7.04 Bn | 6.88 Bn | 338.46 Mn | 76.35 Mn |
| 8 | Chemed | 6.96 Bn | 6.92 Bn | 221.47 Mn | 67.70 Mn |
| 9 | Concentra Group Holdings Parent | 4.52 Bn | 4.38 Bn | 192.10 Mn | 67.30 Mn |
| 10 | Cryo Cell International | 32.09 Mn | 28.93 Mn | 6.10 Mn | 554,586.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 554,586.00 |
| Feb 28, 2026 | 47,108.00 |
| Nov 30, 2025 | -3.63 Mn |
| Aug 31, 2025 | 749,408.00 |
| May 31, 2025 | 355,785.00 |
| Feb 28, 2025 | 282,855.00 |
| Nov 30, 2024 | 301,001.00 |
| Aug 31, 2024 | 1.05 Mn |
| May 31, 2024 | 655,790.00 |
| Feb 29, 2024 | 556,241.00 |
| Nov 30, 2023 | -16.85 Mn |
| Aug 31, 2023 | 680,561.00 |
| May 31, 2023 | 220,976.00 |
| Feb 28, 2023 | 766,812.00 |
| Nov 30, 2022 | 1.47 Mn |
| Aug 31, 2022 | 466,820.00 |
| May 31, 2022 | 634,719.00 |
| Feb 28, 2022 | 832,047.00 |
| Nov 30, 2021 | -285,136.00 |
| Aug 31, 2021 | 856,494.00 |